BAM
ALLO icon

Blueshift Asset Management’s Allogene Therapeutics ALLO Stock Holding History

Blueshift Asset Management’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,811
Closed -$135K – 661
2022
Q1 		$135K Buy
+14,811
New +$154K 0.01% 758
2021
Q2 		– Sell
-12,024
Closed -$424K – 901
2021
Q1 		$424K Buy
+12,024
New +$406K 0.04% 527

Other funds holding ALLO

TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Blueshift Asset Management's ALLO Position: Q2 2022 in Review

Blueshift Asset Management sold out of Allogene Therapeutics (ALLO) in Q2 2022, closing a stake of 14,811 shares — an estimated $135K sold.

Blueshift Asset Management first reported a position in ALLO in Q1 2021 and held it in 2 quarters. The position peaked at $424K in Q1 2021. 161 funds tracked by Wall St. Rank hold ALLO as of Q2 2022.

  • Blueshift Asset Management reported no remaining Allogene Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Blueshift Asset Management sold 14,811 Allogene Therapeutics shares in Q2 2022, an estimated $135K.
  • Blueshift Asset Management first reported a position in Allogene Therapeutics in Q1 2021 and held it in 2 quarters.
  • Blueshift Asset Management's Allogene Therapeutics position peaked at $424K in Q1 2021.
  • 161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2022.

Based on Blueshift Asset Management's 13F filing for Q2 2022, filed 12 Aug 2022.